Esperion Therapeutics, Inc. (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by equities researchers at Northland Securities in a report issued on Wednesday. They presently have a $72.00 price objective on the biopharmaceutical company’s stock. Northland Securities’ price target would indicate a potential upside of 29.99% from the stock’s previous close.

Several other analysts have also commented on ESPR. UBS AG restated a “buy” rating and set a $57.00 price target (up previously from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. Zacks Investment Research lowered shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Deutsche Bank AG set a $64.00 price target on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Stifel Nicolaus restated a “buy” rating and set a $70.00 price target (up previously from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. Finally, Bank of America Corporation restated a “neutral” rating and set a $60.00 price target on shares of Esperion Therapeutics in a research report on Friday, August 11th. Seven investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Esperion Therapeutics has a consensus rating of “Buy” and a consensus target price of $55.35.

Esperion Therapeutics (ESPR) traded up 0.98% on Wednesday, hitting $55.90. 88,948 shares of the company were exchanged. The company’s market capitalization is $1.26 billion. The firm’s 50 day moving average is $49.53 and its 200 day moving average is $42.49. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $57.38.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by ($0.25). During the same quarter in the prior year, the business posted ($0.62) EPS. On average, equities research analysts forecast that Esperion Therapeutics will post ($7.29) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this report can be viewed at https://www.watchlistnews.com/esperion-therapeutics-inc-espr-stock-rating-reaffirmed-by-northland-securities/1612776.html.

Several large investors have recently bought and sold shares of ESPR. Boxer Capital LLC purchased a new position in shares of Esperion Therapeutics in the first quarter worth about $45,020,000. State Street Corp lifted its stake in shares of Esperion Therapeutics by 264.6% in the second quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock worth $69,721,000 after buying an additional 1,093,292 shares in the last quarter. RA Capital Management LLC purchased a new position in shares of Esperion Therapeutics in the first quarter worth about $24,883,000. Discovery Capital Management LLC CT lifted its stake in shares of Esperion Therapeutics by 152.9% in the second quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock worth $44,663,000 after buying an additional 583,529 shares in the last quarter. Finally, Meditor Group Ltd purchased a new position in shares of Esperion Therapeutics in the second quarter worth about $26,194,000. 83.30% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.